Shares of Cellectics (NASDAQ: CLLS), a clinical-stage biopharmaceutical company that specializes in oncology, rose 22.7% this week, according to data from S&P Global Market Intelligence. The company released research data on its new universal CAR (Chimeric Antigen Receptors) T-cell HEAL platform at The American Society of Gene and Cell Therapy's (ASGCT) annual meeting on Monday. In the report, the company said its novel immune-evasive CAR T-cell (ΔTRACCARΔB2MHLAE) showed preclinical promise in fighting acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL).
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting